



AUTAGCO LTD.

(Company Registration No. 200311348E)
(Incorporated in the Republic of Singapore)

**ENTRY INTO A BINDING MEMORANDUM OF UNDERSTANDING FOR STRATEGIC COOPERATION
ON HUMANOID ELDERLY CARE ROBOTS**

1. INTRODUCTION

The board of director (the “**Board**” or “**Directors**”) of Autagco Ltd. (SGX: 1D3) (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that the Company has on 12 November 2025 entered into a legally binding memorandum of understanding (“**MOU**”) with AJJ Medtech Holdings Limited (“**AJJ**”) (each a “**Party**” and collectively, the “**Parties**”). Pursuant to the MOU, the Parties will jointly deploy and commercialise humanoid elderly care robots within the Company’s senior assisted living facilities in Singapore (“**Proposed Strategic Cooperation**”).

2. INFORMATION ON AJJ

AJJ Medtech Holdings Limited (SGX: 584) is a Singapore-incorporated Catalist-listed integrated medical technology group with principal activities encompassing investment holding and the provision of comprehensive medtech solutions. The Group’s core business focuses on research and development of cutting-edge medical technologies, including artificial intelligence systems and robotics applications, complemented by manufacturing capabilities for electromedical equipment and distribution of advanced medical devices and digital healthcare solutions to public health institutes across Singapore and the broader Southeast Asian region.

3. PURPOSE AND SCOPE OF THE MOU

- 3.1** The MOU sets out the Parties’ intention to cooperate in the areas of (i) procurement and deployment, and (ii) clinical trial and application of humanoid elderly care robots co-developed by AJJ and Hangzhou Huaxi Intelligent Technology Co., Ltd. These robots feature core capabilities such as (1) multi-language and dialect support, (2) assisted living care, (3) medical monitoring support and (4) emotional interaction.
- 3.2** The Proposed Strategic Cooperation aims to leverage AJJ’s humanoid robotics and AI capabilities together with the Group’s operational expertise in assisted living to transform traditional elderly care services into AI-powered care environments. It also seeks to promote the commercialisation of elderly care robots in Singapore, providing a model for scalable and high-quality eldercare services.
- 3.3** At the initial stage, subject to the Parties entering into a supply agreement on terms to be mutually agreed, a pilot project involving six (6) units of AJJ-HT-X1 humanoid elderly care robots will be purchased and deployed progressively across the assisted living facilities operated by the Company’s wholly-owned subsidiary, Communa Gold Pte. Ltd. Both Parties shall jointly assess the feasibility and application models of the robots in elderly care scenarios, including clinical validation of companionship, rehabilitation assistance, health monitoring, and cognitive interaction functions. To support algorithm optimisation and service enhancement, data obtained during clinical trial will be anonymised and processed in compliance with the Personal Data Protection Act (PDPA) of Singapore.

3.4 The responsibilities of AJJ shall include:

- (a) clinical trial compliance applications, medical data collection and analysis, and leading communications with regulatory authorities;
- (b) importing of robots and registration with the Health Sciences Authority of Singapore ("HSA");
- (c) leading medical compliance registration and approvals;
- (d) providing robot hardware, core technology, and data analysis capabilities;
- (e) ensuring cybersecurity and compliant storage of medical data; and
- (f) coordinating with Singapore nursing homes, regulatory authorities, and clinical expert teams.

3.5 The responsibilities of the Company shall include:

- (a) providing assisted living locations as sites for clinical trials and deployment;
- (b) reporting the introduction of robots within its assisted living locations to the Ministry of Health under applicable regulations;
- (c) assisting with robot application promotion and staff training within its assisted living locations; and
- (d) implementing pilot applications in its senior assisted living facilities and supporting market development, promotional partnerships, and commercial application implementation.

3.6 Both Parties shall share necessary resources, jointly liaise with relevant local and international medical and elderly care institutions, and ensure the Proposed Strategic Cooperation complies with all applicable laws and regulations.

3.7 The Proposed Strategic Cooperation is non-exclusive and subject to relevant definitive agreements including (but not limited to) supply agreement and licensing agreement that may be negotiated and executed between the Parties. The MOU will remain in force for an initial period of thirty-six (36) months and may be renewed upon mutual agreement.

4. INTERESTS OF THE DIRECTORS AND CONTROLLING SHAREHOLDERS

None of the Directors or controlling shareholders of the Company, as well as their respective associates, has any interest, direct or indirect, in the Proposed Strategic Cooperation (other than through their interests in the shares of the Company, if any).

5. FURTHER ANNOUNCEMENTS

The Company will make further announcements as and when appropriate or upon any material developments in relation to the Proposed Strategic Cooperation.

6. TRADING CAUTION

Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors are advised to refrain from taking any action in respect of their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. In the event

of any doubt, Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors.

BY ORDER OF THE BOARD

Ng Boon Hui
Executive Director and Chief Executive Officer
13 November 2025

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Qi Fang (Tel: (65) 6232 3210), at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.